Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kelun-Biotech Releases Positive Data from TROP-2 ADC in Metastatic Breast Cancer

publication date: Oct 26, 2023

Sichuan Kelun-Biotech reported positive results at the 2023 ESMO conference from a China Phase II trial of its TROP2-ADC as a second-line therapy for patients with HR+/HER2- metastatic breast cancer. SKB264 produced an objective response rate (ORR) of 36.8%, a disease control rate (DCR) of 89.5%, and a 6-month duration of response (DoR) rate of 80%. In 2022, Kelun-Biotech partnered SKB264 with Merck in a $1.4 billion agreement. It was the first of three deals the two companies signed last year with a total value of $12 billion. More details....

Stock Symbol: (HK: 6990)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital